CGC

Canopy Growth Corporation is a Canada-based company operating in the healthcare and consumer sectors within the legal cannabis industry. The company cultivates, processes and commercializes cannabis-derived products for medical, recreational and wellness markets.

Founded in 2013 in Smiths Falls, Ontario, by Bruce Linton and Chuck Rifici, the company emerged during Canada’s early regulatory framework for medical cannabis and amid growing global acceptance of cannabinoid-based therapies.

Its founding purpose was to establish a large-scale, compliant and professionally managed cannabis operation capable of supporting a rapidly expanding industry. Canopy Growth’s portfolio encompasses brands such as Tweed, Tokyo Smoke, Spectrum Therapeutics and Martha Stewart CBD.

The company produces dried flower, extracts, vaporizable products, edibles, infused beverages, capsules, sprays, topical products and pharmaceutical-grade formulations.

Its medical branch develops standardized THC and CBD products for patients under clinical supervision, supported by research programs and partnerships in cannabinoid science.

The company has a global footprint, with established operations in Canada and structured market participation in the United States, as well as presence in Europe, Latin America and strategic international markets.

Its operational infrastructure includes industrial greenhouses, extraction laboratories, processing facilities, R&D centers, distribution networks, compliance units and quality-assurance laboratories aligned with international regulatory requirements.

Market forces influencing Canopy Growth include cannabis legislation, regulatory shifts, consumer demand for medical products, competition with Canadian producers, wholesale-price dynamics, expansion of retail networks, cost structures, supply-chain adjustments, international export rules and macroeconomic conditions affecting discretionary spending.

Trends such as CBD demand, innovation in consumption formats, pharmaceutical-standard production and evolving U.S. legalization pathways significantly shape its strategic direction.

Canopy Growth Corporation’s shares trade on the Nasdaq under the ticker CGC.

History and when Canopy Growth Corporation was founded

Canopy Growth began in 2013 under the name Tweed Marijuana Inc., becoming one of the first companies licensed by the Canadian government to cultivate medical cannabis.

Establishing operations in a former industrial plant in Smiths Falls enabled the company to scale early and adopt a highly regulated cultivation model. Its creation coincided with the launch of Canada’s national medical-cannabis program, which established a foundation for industry development.

In 2014 and 2015, the company expanded its licensed facilities, built distribution capabilities and became the first publicly traded cannabis producer in Canada. This milestone gave the new industry greater legitimacy and allowed Tweed to pursue acquisitions and broader product development.

In 2016, Tweed merged with Bedrocan Canada, forming Canopy Growth Corporation. This merger marked the consolidation of two major players and positioned Canopy as a leading producer with strong scientific, operational and commercial capacity. The company pursued international expansion, diversified its offerings and invested in large-scale production infrastructure.

The legalization of recreational cannabis in Canada in 2018 accelerated demand and drove the company’s significant investments in brand development, product diversification and national retail partnerships.

That same period saw a substantial strategic investment by Constellation Brands, enabling the company to develop cannabinoid-infused beverages and enter emerging wellness segments.

From 2020 to 2024, Canopy Growth underwent operational restructuring to address industry oversupply, pricing pressure and regulatory constraints. The company optimized production, reduced excess capacity, strengthened its U.S. market strategy through compliant subsidiaries and focused on high-margin product categories such as CBD and wellness formulations.

By 2024, Canopy Growth Corporation had established itself as one of the most globally recognized cannabis companies, combining diversified product capabilities, international presence and a strategic orientation toward innovation, efficiency and long-term market maturation.

Additional Information

The Company Canopy Growth Corporation (United States), is listed on Nasdaq with a market value of $ 346.00 Millions, having an equity of $ 549.60 Millions.

With a total of 3.259 employees, the company is listed in the sector of Health and categorized in industry of Pharmaceutical Products.

In the last 12 months the Company had a revenue of $ 200.31 Millions, which generated a loss in the amount of $ -230.75 Millions.

As for its main indicators, the Company has a P/E ratio of -1.50, a P/BV ratio of 0.63 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker CGC.